Processa Pharmaceuticals, Inc. (36)
Browse by Contract Category
Contracts
-
Equity Distribution Agreement, dated August 20, 2021, by and among Processa Pharmaceuticals, Inc. and Oppenheimer & Co. Inc
(Filed With SEC on August 20, 2021)
-
License Agreement dated June 16, 2021
(Filed With SEC on June 17, 2021)
-
Description of Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934
(Filed With SEC on March 25, 2021)
-
Employment Agreement, dated October 6, 2020, between Processa Pharmaceuticals and R. Michael Floyd
(Filed With SEC on October 13, 2020)
-
Addendum No. 1 to the Aposense Ltd. License Agreement
(Filed With SEC on March 25, 2021)
-
Securities Purchase Agreement dated February 16, 2021
(Filed With SEC on February 18, 2021)
-
Form of Placement Agent Warrant
(Filed With SEC on February 18, 2021)
-
Registration Agreement dated February 16, 2021
(Filed With SEC on February 18, 2021)
-
Underwriting Agreement, dated as of October 1, 2020, by and among the Company, Craig-Hallum Capital Group LLC and Benchmark Company, LLC, as representatives of several Underwriters
(Filed With SEC on October 6, 2020)
-
Processa Pharmaceuticals, Inc. 2019 Omnibus Incentive Plan
(Filed With SEC on September 17, 2020)
-
License Agreement with Elion Oncology, Inc
(Filed With SEC on September 17, 2020)
-
Share Issuance Agreement pursuant to License Agreement with Yuhan Corporation
(Filed With SEC on September 17, 2020)
-
License Agreement with Yuhan Corporation
(Filed With SEC on September 17, 2020)
-
License Agreement with Aposense, Ltd. dated May 24, 2020
(Filed With SEC on September 17, 2020)
-
License Agreement with Akashi Therapeutics, Inc. dated August 29, 2019
(Filed With SEC on September 17, 2020)
-
Line of Credit Agreement dated September 20, 2019 between Processa Pharmaceuticals and CorLyst, LLC
(Filed With SEC on September 17, 2020)
-
Line of Credit Agreement dated September 20, 2019 between Processa Pharmaceuticals and DKBK Enterprises, LLC
(Filed With SEC on September 17, 2020)
-
Employment Agreement dated September 5, 2018, between Processa and James Stanker
(Filed With SEC on September 17, 2020)
-
Asset Purchase Agreement. Dated October 2, 2017, among the Company, Promet Therapeutics LLC and Processa Therapeutics LLC
(Filed With SEC on September 17, 2020)
-
License Option Agreement with CoNCERT
(Filed With SEC on September 17, 2020)
-
Amended and Restated 2011 Equity Incentive Plan
(Filed With SEC on September 17, 2020)
-
Form of Warrant
(Filed With SEC on September 17, 2020)
-
Form of Subscription Agreement for Senior Convertible Notes
(Filed With SEC on September 17, 2020)
-
Warrants issued to Boustead Securities
(Filed With SEC on September 17, 2020)
-
Warrant issued to PoC Capital, LLC
(Filed With SEC on September 17, 2020)
-
Specimen of Common Stock Certificate
(Filed With SEC on September 17, 2020)
-
Amendment to License Agreement and Securities Purchase Agreement with CoNCERT Pharmaceuticals
(Filed With SEC on September 17, 2020)
-
Form of Underwriting Agreement
(Filed With SEC on September 17, 2020)
-
License Agreement by and between Processa Pharmaceuticals and Elion Oncology dated August 23, 2020
(Filed With SEC on August 27, 2020)
-
Share Issuance Agreement by and between Processa Pharmaceuticals, Inc. and Yuhan Corporation, dated August 19, 2020
(Filed With SEC on August 20, 2020)
-
License Agreement by and between Processa Pharmaceuticals, Inc. and Yuhan Corporation, dated August 19, 2020
(Filed With SEC on August 20, 2020)
-
Promissory Note, dated May 1, 2020, with Processa Pharmaceuticals, Inc. and Bank of America, N.A., received by the company under the Small Business Administration Paycheck...
(Filed With SEC on July 17, 2020)
-
Form of 8% Senior Convertible Notes
(Filed With SEC on December 13, 2019)
-
Line of Credit Agreement dated September 20, 2019 between Processa Pharmaceuticals and CorLyst, LLC
(Filed With SEC on October 3, 2019)
-
Amendment to the Agreement between PoC Capital and Processa Pharmaceuticals, Inc. dated September 30, 2019
(Filed With SEC on October 3, 2019)
-
Line of Credit Agreement dated September 20, 2019 between Processa Pharmaceuticals and DKBK Enterprises, LLC
(Filed With SEC on October 3, 2019)
